Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsFRA:HTD +0.29%85 Days Sales Outstanding is 20.64 as of Jun. 2026, which is 23% below its 10-year median of 26.75. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €59.43 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 835 Biotechnology companies, Corcept Therapeutics ranks better than 86.11% on this metric.
Corcept Therapeutics (FRA:HTD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Corcept Therapeutics Days Sales Outstanding Related Terms
Corcept Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HTD vs APGE, KRYS, NUVL: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Days Sales Outstanding falls into.
Corcept Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (FRA:HTD) has a Days Sales Outstanding of 20.64 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Corcept Therapeutics and its competitors. This is 23% below median its historical median of 26.75. Over the past decade, Corcept Therapeutics' Days Sales Outstanding has ranged from 22.34 to 36.09. According to the industry distribution chart, Corcept Therapeutics ranks #116 out of 835 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Corcept Therapeutics' Days Sales Outstanding too high?
Corcept Therapeutics' current Days Sales Outstanding of 20.64 is 23% below median its 10-year median of 26.75. Over the past 10 years, this metric has ranged from a low of 22.34 to a high of 36.09. The Biotechnology industry median Days Sales Outstanding is 68.94. Corcept Therapeutics' value of 20.64 is 70.1% below this industry median. Based on the distribution chart, Corcept Therapeutics ranks #116 out of 835 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Days Sales Outstanding compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #116 out of 835 companies for Days Sales Outstanding. This places Corcept Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.94. Corcept Therapeutics' value of 20.64 is 70.1% below this benchmark. Historically, Corcept Therapeutics' own Days Sales Outstanding has ranged from 22.34 to 36.09 over the past decade. While the company's 10-year median is 26.75 vs. the industry median of 68.94, Corcept Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Days Sales Outstanding of 20.64 is 70.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Days Sales Outstanding is 20.64, which is 23% below median its own 10-year median of 26.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €59.43, compared to a current price of €104.55 — trading 75.9% above its estimated fair value. The current Days Sales Outstanding is 20.64, which is 23% below median its 10-year median of 26.75 and 70.1% below the Biotechnology industry median of 68.94. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Days Sales Outstanding is 20.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €104.55 is trading 75.9% above its estimated GF Value™ of €59.43.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
Days Sales Outstanding: 20.64 (23% below median its 10-year median of 26.75)
GF Value™: €59.43 vs. price of €104.55 (75.9% above fair value)
Industry Position: 70.1% below the Biotechnology median (#116 of 835)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for FRA:HTD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
